

Press release

Cham, November 27, 2023

Oncoteq completes another in-licensing deal, adding a potential best-in-class CD30 antibody drug conjugate from Tubulis to its oncology pipeline

- Oncoteq, a biotech company specializing in innovative cancer treatments, gains exclusive global development rights for potential best-in-class antibody drug conjugate TEQ102 (formerly TUB-010) from Tubulis, aimed at treating T-cell and Hodgkin's lymphomas
- TEQ102 was developed utilizing Tubulis' superior linker technology which enables highly selective and reliable delivery of a cytotoxic agent to CD30-expressing cancer cells
- Based on its favorable drug properties and design, TEQ102 has the potential to deliver higher and more effective doses and enable longer term treatment to improve treatment outcomes and quality of life of patients
- TEQ102 taps into a market projected to exceed annual revenues of USD 3bn
- This is Oncoteq's second in-licensing deal in recent weeks, executing its strategy to build a compelling pipeline through deal-making and to unlock the hidden value of assets utilizing a proprietary artificial intelligence platform

Oncoteq AG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibody drug conjugate (ADC) TEQ102 from biotech company Tubulis for the treatment of patients with CD30-positive lymphomas, including, but not limited to, T-cell and Hodgkin's lymphomas. Patients with these types of lymphomas and whose disease recur are faced with limited treatment options that have relatively poor long-term outcomes.

TEQ102 was designed and developed by Tubulis, a biotechnology company based in Munich, Germany. The ADC utilizes the documented efficacy of CD30-directed anti-tumor treatment while optimizing tolerability through the superior improved linker technology. Drug safety and tolerability enhanced with such optimization may enable longer treatment and/or higher dosages of the ADC which is expected to result in greater efficacy as compared with the limited number of treatment courses and dosages that can currently be delivered with known anti-CD30 ADCs. TEQ102 is therefore designed to improve treatment outcomes and quality of life of lymphoma patients.

TEQ102 targets a market currently valued at USD ~1.5bn but expected to grow towards USD 3bn in the coming years, representing a significant commercial opportunity.

Mads Dalsgaard, Chief Executive Officer of Oncoteq, comments: *"We are excited to again execute on our strategy to build a pipeline of promising future cancer treatments and to secure rights to what can be a significant improvement in treatment options for patients with CD30-positive lymphomas."*

TEQ102 has the potential to be superior to current therapies and addresses a marked unmet medical need. We are looking forward to quickly advancing the development of the compound towards clinical testing.”

Dominik Schumacher, Chief Executive Officer, and co-founder of Tubulis, adds: *“This licensing agreement with Oncoteq further validates our differentiated ADC development platform and technology, demonstrating we can deliver a clinical stage-ready and therapeutically relevant drug candidate. The Oncoteq team brings the right expertise and knowledge to advance TEQ102 through clinical development to deliver the highest benefits for patients, while we continue to develop and expand our growing, innovative pipeline of ADCs uniquely matched for patients with solid tumors.”*

Under the terms of the agreement, Oncoteq obtains a worldwide exclusive license for the development and commercialization of TEQ102. Tubulis will be entitled to an upfront payment as well as development-based milestone payments and royalties on future sales.

For further information and interview with Chief Executive Officer Mads Dalsgaard, please contact:

Mads Kronborg, Advisor

Element 115 Reputation Management

E: mads@element115.dk

T: +45 60 51 49 55

About TEQ102

TEQ102 (formerly TUB-010) is a highly stable ADC with favorable drug properties. It consists of a well-characterized anti-CD30 antibody, the innovative TubTag® technology linker and the clinically well-established cytotoxic agent monomethyl-auristatin E. Tubulis’ unique TubTag® technology enables the development of homogenous and highly stable ADCs with reliable drug-antibody ratios, reduced aggregation potential and no premature cleavage. TEQ102 will be investigated in patients with CD30-positive lymphomas to evaluate its potential to deliver a more efficacious and better tolerated solution for CD30-directed treatment with the goal of improving quality of life and treatment outcomes for patients living with these diseases.

About Oncoteq

Established in 2022, Oncoteq is a clinical stage biotech company specializing in innovative cancer treatments. Combining AI technology from its sister company Innoplexus (www.innoplexus.com) and Oncoteq’s scientific and medical expertise allows the company to identify molecules that could become effective medicines but are no longer prioritized by current owners. Further, the AI platform is leveraged to optimize and de-risk clinical development plans. Oncoteq is founded and seeded by Cureteq AG and headquartered in Cham, Switzerland. Cureteq AG is an asset management and drug development company with focus on oncology, central nervous systems disorders, rare diseases and

women's health. For further information please visit Oncoteq website www.oncoteq.ch and Cureteq website www.cureteq.com and LinkedIn-page: <https://www.linkedin.com/company/cureteq/>.

About Tubulis

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its growing pipeline and will continue to collaborate with industry partners to usher in a new ADC era and deliver better outcomes for patients. Visit Tubulis website www.tubulis.com or follow us on LinkedIn <https://www.linkedin.com/company/tubulis/> and Twitter https://twitter.com/Tubulis_GmbH.